


A



B




Figure S1 Mutation rates of concomitant genomic alterations in carriers of different types of TP53 mutations (TP53-MUTs) among (A) patients with lung adenocarcinoma (LUAD) or (B) patients with lung squamous cell carcinoma (LUSC).




Figure S2 The tumor mutation burden (TMB) levels of (A-D) patients with lung adenocarcinoma (LUAD) or (E-G) those with squamous cell carcinoma (LUSC) carrying the indicated subtypes of TP53 mutations (TP53-MUTs).




Figure S3 Kaplan-Meier survival plots showing the disease-free survival (DFS) rates of patients with lung adenocarcinoma (LAUD), stratified by (A) TP53 mutation (TP53-MUT) status or (B-E) different classes of TP53-MUTSs.




Figure S4 Kaplan-Meier survival plots showing the disease-free survival (DFS) rates of patients with lung squamous cell carcinoma (LUSC), stratified by (A) TP53 mutation (TP53-MUT) status or (B-E) different classes of TP53-MUTs.




Figure S5 Multivariate analysis of prognostic factors for overall survival (OS) in patients with resectable stage I-III lung adenocarcinoma (LAUD) (n=470). **, P<0.01; ***, P<0.001